



FONDAZIONE CAVALIERI OTTOLENGHI

### Mercoledì 10 aprile, h 14

Aula blu, Polo didattico A.O.U. San Luigi Gonzaga Orbassano (TO)

# «Monitoring Health and Disease Progression with Ultrasensitive Biomarker Analysis»













#### Speaker:

Dott. Francesco Piraino
Field Application Scientist,
Quanterix, Inc

www.quanterix.com

#### Ospite:

Dott. Antonio Bertolotto

NICO

Neurologia, CReSM

AOU San Luigi Gonzaga



## Join us Wednesday, April 10 at 14:00

# Monitoring Health and Disease Progression with Ultrasensitive Biomarker Analysis











Speaker: Francesco Piraino, PhD - Quanterix, Inc.

- Quanterix Simoa™ technology detects proteins with 1000-fold higher sensitivity than traditional immunoassays
- Ultrasensitive detection is enabling the identification of more informative biomarkers requiring less invasive and less expensive testing procedures to improve our understanding of neurodegenerative disease.
- Simoa assays are currently applied across various therapeutic areas including neurology, oncology, cardiology, inflammation and infectious disease to detect biomarkers in a variety of sample matrices.
- Quanterix cytokine assays lead the field with respect to precision, disease correlation and detection of endogenous analytes.
- Quanterix offers a large menu of commercially available assays, an open instrument platform for developing homebrew assays, and assay testing services.